At present, only the ACE inhibitor captopril is approved for the therapy of nephropathy associated with type 1 diabetes and the angiotensin II receptor blocker (ARB) losartan for the therapy of nephropathy associated with type 2 diabetes [44, 45]. Here, ACE is linked to kidney disorder.